DiNAQOR plans to open its own GMP manufacturing facility which will be located at Bio-Technopark Schlieren-Zürich.
State-of-the-art facility is laid with an area covering 1200 sqm (13,000 sq. ft). The new GMP facility will be located alongside R &D facility to produce adeno-associated virus (AAV)-based gene therapies.
The construction of the new manufacturing facility doubles the size of the current capacity. Moreover, it will be committed in forming a GMP-compatible process in the Process Development labsthus enabling on-site tech transfer for GMP manufacturing of viral vectors at 500L scale.In addition, it will also produce clinical-grade material up toPhase 3 development of DiNAQOR's pipeline.
After the construction of the new GMP facility the Process and Analytical Development, Quality Control and GMP capabilities will remain in the same location alongside of DiNAQOR R & D facility.
The construction of the GMP facility is expected to complete in the second quarter of 2022 and provide 50 new jobs.